Intrapatient variability of tacrolimus trough concentrations and its effect on serum creatinine level in kidney transplant recipients treated with nematvir/ritonavir
-
摘要:
目的 探讨奈玛特韦/利托那韦治疗下肾移植受者他克莫司谷浓度个体内变异度（IPV）情况及其对血清肌酐（Scr）的影响。 方法 收集41例使用奈玛特韦/利托那韦治疗新型冠状病毒感染的肾移植受者的临床资料，总结奈玛特韦/利托那韦与他克莫司使用情况，分析他克莫司谷浓度分布情况及目标浓度达标率，以及他克莫司谷浓度的IPV分布及其与Scr变化的相关性。 结果 41例肾移植受者中，足量和低剂量使用奈玛特韦/利托那韦的各占46%（19/41），高剂量使用奈玛特韦/利托那韦的占7%（3/41）。95%（39/41）的患者在使用奈玛特韦/利托那韦前24 h停用他克莫司，5%（2/41）的患者在使用奈玛特韦/利托那韦后24 h停用他克莫司；所有患者在奈玛特韦/利托那韦5 d疗程结束至少3 d后开始重新启用他克莫司。服药前、服药期间、停药1周、停药2周、停药1个月他克莫司谷浓度达标率分别为73%（30/41）、30%（3/10）、48%（15/31）、35%（11/31）、53%（16/30）。IPV中位数为35%（23%，51%），Spearman相关性分析结果显示，受者的Scr升高倍数与IPV呈正相关（rs=0.400 7，P=0.028 2）。 结论 奈玛特韦/利托那韦治疗下肾移植受者他克莫司谷浓度达标率降低，他克莫司谷浓度的IPV升高，且IPV较高的受者更容易引起Scr升高。 Abstract:Objective To investigate the intra-patient variability (IPV) of tacrolimus trough concentrations and its effect on serum creatinine (Scr) level in kidney transplant recipients treated with nematvir/ritonavir. Methods Clinical data of 41 kidney transplant recipients infected by SARS-CoV-2 and treated with nematvir/ritonavir were collected. The usage of nematvir/ritonavir and tacrolimus was summarized. The distribution of tacrolimus trough concentrations and the attainment rate of target concentration were analyzed. The correlation between the IPV distribution of tacrolimus trough concentrations and the changes of Scr level was determined. Results Among 41 kidney transplant recipients, 46%(19/41) were given with full- and low-dose nematvir/ritonavir, and 7%(3/41) were given with high-dose nematvir/ritonavir. Use of tacrolimus was discontinued at 24 h before nematvir/ritonavir treatment in 95%(39/41) patients, and at 24 h after use of nematvir/ritonavir in 5%(2/41) patients. Tacrolimus was given at least 3 d after the 5-d course of nematvir/ritonavir in all patients. The attainment rate of tacrolimus trough concentration was 73%(30/41), 30%(3/10), 48%(15/31), 35%(11/31) and 53%(16/30) before, during, 1 week, 2 weeks and 1 month after use of nematvir/ritonavir, respectively. The median IPV was 35%(23%, 51%). Spearman correlation analysis showed that the increase of Scr level was positively correlated with IPV (rs=0.400 7, P=0.028 2). Conclusions The attainment rate of tacrolimus trough concentration is declined in kidney transplant recipients treated with nematvir/ritonavir. The IPV of tacrolimus trough concentrations is elevated. The recipients with higher IPV are prone to an elevation in Scr level. -
图 1 奈玛特韦/利托那韦治疗下他克莫司谷浓度分布情况及目标浓度达标率
Figure 1. Distribution of trough concentration of tacrolimus and rate of reaching the target concentration under nematvir/ritonavir treatment
-
[1] BRUNET M, VAN GELDER T, ÅSBERG A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307. DOI: 10.1097/FTD.0000000000000640. [2] OBERBAUER R, BESTARD O, FURIAN L, et al. Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives[J]. Transplant Rev (Orlando), 2020, 34(2): 100531. DOI: 10.1016/j.trre.2020.100531. [3] 刘冬雪, 陈頔, 王洋, 等. 他克莫司的药品不良反应及药物相互作用文献分析[J]. 中国医院用药评价与分析, 2020, 20(9): 1122-1124, 1128. DOI: 10.14009/j.issn.1672-2124.2020.09.026.LIU DX, CHEN D, WANG Y, et al. Literature analysis of adverse drug reactions and drug interaction of tacrolimus[J]. Eval Anal Drug Use Hosp China, 2020, 20(9): 1122-1124, 1128. DOI: 10.14009/j.issn.1672-2124.2020.09.026. [4] 吴云, 王家莹, 卢映蓉, 等. 器官移植患者他克莫司血药浓度影响因素的研究进展[J]. 医药导报, 2022, 41(5): 669-674. DOI: 10.3870/j.issn.1004-0781.2022.05.013.WU Y, WANG JY, LU YR, et al. Research progress on influencing factors of tacrolimus concentration in patients undergoing organ transplant[J]. Herald Med, 2022, 41(5): 669-674. DOI: 10.3870/j.issn.1004-0781.2022.05.013. [5] NUCHJUMROON A, VADCHARAVIVAD S, SINGHAN W, et al. Comparison of tacrolimus intra-patient variability during 6-12 months after kidney transplantation between CYP3A5 expressers and nonexpressers[J]. J Clin Med, 2022, 11(21): 6320. DOI: 10.3390/jcm11216320. [6] GOLD A, TÖNSHOFF B, DÖHLER B, et al. Association of graft survival with tacrolimus exposure and late intra-patient tacrolimus variability in pediatric and young adult renal transplant recipients-an international CTS registry analysis[J]. Transpl Int, 2020, 33(12): 1681-1692. DOI: 10.1111/tri.13726. [7] KUYPERS DRJ. Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome[J]. Clin Pharmacol Ther, 2020, 107(2): 347-358. DOI: 10.1002/cpt.1618. [8] 王钊, 刘鹤松, 王秀云. 奈玛特韦片/利托那韦片药物相互作用与用药指导[J]. 临床药物治疗杂志, 2023, 21(1): 21-26. DOI: 10.3969/j.issn.1672-3384.2023.01.004.WANG Z, LIU HS, WANG XY. Drug interaction and clinical medication guidance of nirmatrelvir/ritonavir tablets[J]. Clin Med J, 2023, 21(1): 21-26. DOI: 10.3969/j.issn.1672-3384.2023.01.004. [9] RAZONABLE RR, O'HORO JC, HANSON SN, et al. Comparable outcomes for bebtelovimab and ritonavir-boosted nirmatrelvir treatment in high-risk patients with coronavirus disease-2019 during severe acute respiratory syndrome coronavirus 2 BA. 2 Omicron epoch[J]. J Infect Dis, 2022, 226(10): 1683-1687. DOI: 10.1093/infdis/jiac346. [10] DEVRESSE A, SÉBASTIEN BRIOL, DE GREEF J, et al. Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2[J]. Kidney Int Rep, 2022, 7(11): 2356-2363. DOI: 10.1016/j.ekir.2022.08.026. [11] FISHBANE S, HIRSCH JS, NAIR V. Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection[J]. Am J Kidney Dis, 2022, 79(4): 480-482. DOI: 10.1053/j.ajkd.2022.01.001. [12] WANG Z, CHAN ECY. Physiologically-based pharmacokinetic modeling-guided dose management of oral anticoagulants when initiating nirmatrelvir/ritonavir (paxlovid) for COVID-19 treatment[J]. Clin Pharmacol Ther, 2022, 112(4): 803-807. DOI: 10.1002/cpt.2687. [13] LEMAITRE F, BUDDE K, VAN GELDER T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19[J]. Ther Drug Monit, 2023, 45(2): 191-199. DOI: 10.1097/FTD.0000000000001014. [14] BADRI P, DUTTA S, COAKLEY E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir[J]. Am J Transplant, 2015, 15(5): 1313-1322. DOI: 10.1111/ajt.13111. [15] KWON EJ, YUN GA, PARK S, et al. Treatment of acute tacrolimus toxicity with phenytoin after paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient[J]. Kidney Res Clin Pract, 2022, 41(6): 768-770. DOI: 10.23876/j.krcp.22.218. [16] SHAH A, NASRULLAH A, BUTT MA, et al. Paxlovid with caution: novel case of paxlovid-induced tacrolimus toxicity in a cardiac transplant patient[J]. Eur J Case Rep Intern Med, 2022, 9(9): 003528. DOI: 10.12890/2022_003528. [17] HIREMATH S, MCGUINTY M, ARGYROPOULOS C, et al. Prescribing nirmatrelvir/ritonavir for COVID-19 in advanced CKD[J]. Clin J Am Soc Nephrol, 2022, 17(8): 1247-1250. DOI: 10.2215/CJN.05270522. [18] 中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical application of immunosuppressive agents in organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001. [19] WALLEMACQ P, ARMSTRONG VW, BRUNET M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference[J]. Ther Drug Monit, 2009, 31(2): 139-152. DOI: 10.1097/FTD.0b013e318198d092. [20] VAN GELDER T, MEZIYERH S, SWEN JJ, et al. The clinical impact of the C0/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients[J]. Front Pharmacol, 2020, 11: 1142. DOI: 10.3389/fphar.2020.01142. [21] MENDOZA ROJAS A, HESSELINK DA, VAN BESOUW NM, et al. High tacrolimus intrapatient variability and subtherapeutic immunosuppression are associated with adverse kidney transplant outcomes[J]. Ther Drug Monit, 2022, 44(3): 369-376. DOI: 10.1097/FTD.0000000000000955. [22] SHUKER N, SHUKER L, VAN ROSMALEN J, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation[J]. Transpl Int, 2016, 29(11): 1158-1167. DOI: 10.1111/tri.12798. [23] BECKER-COHEN R. Pathophysiological implications of variability in blood tacrolimus levels in pediatric and adolescent kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2022, 17(8): 1105-1106. DOI: 10.2215/CJN.06640622. [24] LARPPARISUTH N, PONGNATCHA T, PANPROM P, et al. High intrapatient variability in tacrolimus exposure calculated over a long period is associated with de novo donor-specific antibody development and/or late rejection in thai kidney transplant patients receiving concomitant CYP3A4/5 inhibitors[J]. Ther Drug Monit, 2021, 43(5): 624-629. DOI: 10.1097/FTD.0000000000000850. [25] MENDOZA ROJAS A, HESSELINK DA, VAN BESOUW NM, et al. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients[J]. Expert Rev Clin Immunol, 2019, 15(12): 1323-1331. DOI: 10.1080/1744666X.2020.1693263. [26] BAGHAI ARASSI M, GAUCHE L, SCHMIDT J, et al. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk[J]. Pediatr Nephrol, 2022, 37(10): 2503-2514. DOI: 10.1007/s00467-022-05426-3. [27] URZÌ BRANCATI V, SCARPIGNATO C, MINUTOLI L, et al. Use of pharmacogenetics to optimize immunosuppressant therapy in kidney-transplanted patients[J]. Biomedicines, 2022, 10(8): 1798. DOI: 10.3390/biomedicines10081798. [28] YU M, LIU M, ZHANG W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation[J]. Curr Drug Metab, 2018, 19(6): 513-522. DOI: 10.2174/1389200219666180129151948. [29] BERAR YANAY N, BOGNER I, SAKER K, et al. Paxlovid-tacrolimus drug-drug interaction in a 23-year-old female kidney transplant patient with COVID-19[J]. Clin Drug Investig, 2022, 42(8): 693-695. DOI: 10.1007/s40261-022-01180-4. [30] YOUNG C, PAPIRO T, GREENBERG JH. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (paxlovid) for COVID-19 infection in a child with a kidney transplant[J]. Pediatr Nephrol, 2023, 38(4): 1387-1388. DOI: 10.1007/s00467-022-05712-0. [31] SINDELAR M, MCCABE D, CARROLL E. Tacrolimus drug-drug interaction with nirmatrelvir/ritonavir (paxlovidTM) managed with phenytoin[J]. J Med Toxicol, 2023, 19(1): 45-48. DOI: 10.1007/s13181-022-00922-2. [32] PRIKIS M, CAMERON A. Paxlovid (nirmatelvir/ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report[J]. Transplant Proc, 2022, 54(6): 1557-1560. DOI: 10.1016/j.transproceed.2022.04.015. [33] BELDEN KA, YEAGER S, SCHULTE J, et al. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time"[J]. Transpl Infect Dis, 2023, 25(2): e14037. DOI: 10.1111/tid.14037. [34] STADER F, KHOO S, STOECKLE M, et al. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect[J]. J Antimicrob Chemother, 2020, 75(10): 3084-3086. DOI: 10.1093/jac/dkaa253. [35] MARZOLINI C, KURITZKES DR, MARRA F, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications[J]. Clin Pharmacol Ther, 2022, 112(6): 1191-1200. DOI: 10.1002/cpt.2646. -
下载:
点击查看大图
图(3)
计量
- 文章访问数: 236
- HTML全文浏览量: 53
- PDF下载量: 55
- 被引次数: 0
